caa a22 4500 397562152 CHVBK 20180308164818.0 cr unu---uuuuu 161202e19960807xx s 000 0 eng 10.1093/jnci/88.15.1060 doi (NATIONALLICENCE)oxford-10.1093/jnci/88.15.1060 Male Sexual Behavior and Human Papillomavirus DNA: Key Risk Factors for Cervical Cancer in Spain [Elektronische Daten] [F. Xavier Bosch, Xavier Castellsagué, Nubia Muñoz, Silvia de Sanjosé, Anthony M. Ghaffari, Luís C. González, Miguel Gili, Isabel Izarzugaza, Pau Viladiu, Carmen Navarro, Alberto Vergara, Nieves Ascunce, Eloisa Guerrero, Keerti V. Shah] Background: It is now established that certain types of human papillomaviruses (HPVs) are the sexually transmitted agents etiologically linked to cervical cancer. Studies assessing the contribution of the male's sexual behavior and genital HPV DNA status to the risk of development of cervical neoplasia in sexual partners have yielded inconsistent results. Purpose: This study evaluates the role of men's sexual behavior and the presence of HPV DNA in the penis on the development of cervical cancer in their sexual partners in Spain, a low-risk area for cervical neoplasia. Methods: Husbands (n = 633) of women participating in two case-control studies of cervical neoplasia were interviewed to obtain information on lifestyle habits, including sexual practices. Cytologic samples were taken from the distal urethra and the surface of the glans penis of 183 husbands of case women and of 171 husbands of control women. These samples were analyzed by a polymerase chain reaction-based system using a generic probe and 25 type-specific probes for the detection and typing of HPV DNA. Serologic specimens were also obtained and analyzed for antibodies to Chlamydia trachomatis, Treponema pallidum, herpes simplex virus type II, and Neisseria gonorrhoeae. Results: The presence of HPV DNA in the husbands' penis conveyed a fivefold risk of cervical cancer to their wives (adjusted odds ratio [OR] for HPV DNA positivity = 4.9; 95% confidence interval [CI] = 1.9-12.6). The risk of cervical cancer was strongly related to HPV type (adjusted OR for HPV type 16 = 9.0; 95% CI = 1.1-77.5), to the husbands' number of extramarital partners (adjusted OR = 11.0; 95% CI = 3.0-40.0; for ≥21 women versus one), and to the number of prostitutes as extramarital sexual partners (adjusted OR = 8.0; 95% CI = 2.9-22.2; for ≥10 women versus none). Presence of antibodies to C. trachomatis (adjusted OR = 2.6; 95% CI = 1.4-4.6) and an early age at first sexual intercourse of the husband (adjusted OR = 3.2; 95% CI = 1.7-5.9; for ≤15 years versus ≥21 years) were also associated with cervical neoplasia in the wife. After adjustment for these variables and for the wife's pack-years of smoking, the husband's smoking was moderately associated with cervical cancer in his wife (adjusted OR = 2.5; 95% CI = 1.4-4.4; for ≥26.2 pack-years versus none). Conclusions: The study supports the role of men as vectors of the HPV types that are related to cervical cancer. Lifetime number of female sexual partners, number of female prostitutes as sexual partners, and detection of HPV DNA in the penis of husbands are all surrogate markers of exposure to HPV during marriage. Implications: Men who report multiple sexual partners or who are carriers of HPV DNA may be vectors of high-risk HPV types and may place their wives at high risk of developing cervical cancer. Prostitutes are an important reservoir of high-risk HPVs. [J Natl Cancer Inst 1996; 88: 1060-7] © Oxford University Press REPORTS nationallicence Bosch F. Xavier Servei d'Epidemiologia i Registre del Cancer, Institut Catalá d'Oncologia, L'Hospitalet de Llobregat Barcelona, Spain aut Castellsagué Xavier Servei d'Epidemiologia i Registre del Cancer, Institut Catalá d'Oncologia, L'Hospitalet de Llobregat Barcelona, Spain aut Muñoz Nubia Unit of Field and Intervention Studies, International Agency for Research on Cancer Lyon, France aut de Sanjosé Silvia Servei d'Epidemiologia i Registre del Cancer, Institut Catalá d'Oncologia, L'Hospitalet de Llobregat Barcelona, Spain aut Ghaffari Anthony M. Department of Immunology and Infectious Diseases, The Johns Hopkins University, School of Medicine Baltimore, MD aut González Luís C. Servicio Territorial de Sanidad y Bienestar Social, Junta de Castilla y Leon Salamanca, Spain aut Gili Miguel Facultad de Medicina, Universidad de Sevilla Spain aut Izarzugaza Isabel Departamento de Sanidad y Consumo Gobierno Vasco, Vitoria-Gasteiz, Spain aut Viladiu Pau Hospital de Santa Caterina Girona, Spain aut Navarro Carmen Consejeria de Sanidad Murcia, Spain aut Vergara Alberto Servicio Provincial de Sanidad Zaragoza, Spain aut Ascunce Nieves Programa de Cancer de Mama Pamplona, Spain aut Guerrero Eloisa Department of Immunology and Infectious Diseases, The Johns Hopkins University, School of Medicine Baltimore, MD aut Shah Keerti V. Department of Immunology and Infectious Diseases, The Johns Hopkins University, School of Medicine Baltimore, MD aut JNCI: Journal of the National Cancer Institute Oxford University Press 88/15(1996-08-07), 1060-1067 0027-8874 88:15<1060 1996 88 jnci https://doi.org/10.1093/jnci/88.15.1060 text/html Onlinezugriff via DOI 1 other jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jnci/88.15.1060 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Bosch F. Xavier Servei d'Epidemiologia i Registre del Cancer, Institut Catalá d'Oncologia, L'Hospitalet de Llobregat Barcelona, Spain aut NATIONALLICENCE 700 1- Castellsagué Xavier Servei d'Epidemiologia i Registre del Cancer, Institut Catalá d'Oncologia, L'Hospitalet de Llobregat Barcelona, Spain aut NATIONALLICENCE 700 1- Muñoz Nubia Unit of Field and Intervention Studies, International Agency for Research on Cancer Lyon, France aut NATIONALLICENCE 700 1- de Sanjosé Silvia Servei d'Epidemiologia i Registre del Cancer, Institut Catalá d'Oncologia, L'Hospitalet de Llobregat Barcelona, Spain aut NATIONALLICENCE 700 1- Ghaffari Anthony M. Department of Immunology and Infectious Diseases, The Johns Hopkins University, School of Medicine Baltimore, MD aut NATIONALLICENCE 700 1- González Luís C. Servicio Territorial de Sanidad y Bienestar Social, Junta de Castilla y Leon Salamanca, Spain aut NATIONALLICENCE 700 1- Gili Miguel Facultad de Medicina, Universidad de Sevilla Spain aut NATIONALLICENCE 700 1- Izarzugaza Isabel Departamento de Sanidad y Consumo Gobierno Vasco, Vitoria-Gasteiz, Spain aut NATIONALLICENCE 700 1- Viladiu Pau Hospital de Santa Caterina Girona, Spain aut NATIONALLICENCE 700 1- Navarro Carmen Consejeria de Sanidad Murcia, Spain aut NATIONALLICENCE 700 1- Vergara Alberto Servicio Provincial de Sanidad Zaragoza, Spain aut NATIONALLICENCE 700 1- Ascunce Nieves Programa de Cancer de Mama Pamplona, Spain aut NATIONALLICENCE 700 1- Guerrero Eloisa Department of Immunology and Infectious Diseases, The Johns Hopkins University, School of Medicine Baltimore, MD aut NATIONALLICENCE 700 1- Shah Keerti V. Department of Immunology and Infectious Diseases, The Johns Hopkins University, School of Medicine Baltimore, MD aut NATIONALLICENCE 773 0- JNCI: Journal of the National Cancer Institute Oxford University Press 88/15(1996-08-07), 1060-1067 0027-8874 88:15<1060 1996 88 jnci Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford